Depomed Announces Extended Results for Furosemide GR in CHF Patients

Depomed has announced results from its extended Phase II trial of Furosemide GR, a controlled-release formulation of the leading diuretic furosemide, which is used to treat edema in congestive heart failure (CHF) patients.

Additional data from 10 patients who underwent additional treatment indicated that Furosemide GR continued to produce comparable diuresis to immediate-release furosemide, however with variable urinary urgency and frequency between the two treatment groups.

The company indicated that while it is re-evaluating the program, resources that were dedicated to Furosemide GR development will be reallocated to grow its pipeline with new programs as well as support its other late stage programs, including two products, Glumetza and Proquin XR, both under review at the FDA, and another product, Gabapentin GR, currently in Phase II clinical testing. The company may choose to conduct additional development of Furosemide GR in a different patient population at a later time.